Skip to main content
Erschienen in: Endocrine 2/2017

13.10.2016 | Research Letter

Circulating periostin in patients with nonalcoholic fatty liver disease

verfasst von: Stergios A. Polyzos, Jannis Kountouras, Athanasios D. Anastasilakis, Athanasios Papatheodorou, Panagiotis Kokkoris, Evangelos Terpos

Erschienen in: Endocrine | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Excerpt

Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, ranges from nonalcoholic simple steatosis (SS) to nonalcoholic steatohepatitis (NASH), characterized by inflammation and/or fibrosis, and to NASH-related cirrhosis and hepatocellular carcinoma [1]. Liver biopsy still is regarded as the reference for the diagnosis of NAFLD, although identification of noninvasive biomarkers is a field of intense research, expected to help both clinical trials and clinical practice, which are to date impaired due to the need of paired biopsies [2]. …
Literatur
1.
Zurück zum Zitat S.A. Polyzos, J. Kountouras, C. Zavos, Nonalcoholic fatty liver disease: The pathogenetic roles of insulin resistance and adipocytokines. Curr. Mol. Med. 72, 299–314 (2009)CrossRef S.A. Polyzos, J. Kountouras, C. Zavos, Nonalcoholic fatty liver disease: The pathogenetic roles of insulin resistance and adipocytokines. Curr. Mol. Med. 72, 299–314 (2009)CrossRef
2.
Zurück zum Zitat S.A. Polyzos, C.S. Mantzoros, Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 63, 161–167 (2014)CrossRef S.A. Polyzos, C.S. Mantzoros, Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 63, 161–167 (2014)CrossRef
3.
Zurück zum Zitat A.Y. Liu, H. Zheng, G. Ouyang, Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix. Biol. 37, 150–156 (2014)CrossRef A.Y. Liu, H. Zheng, G. Ouyang, Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix. Biol. 37, 150–156 (2014)CrossRef
4.
Zurück zum Zitat S.A. Polyzos, A.D. Anastasilakis, Periostin on the road to nonalcoholic fatty liver disease. Endocrine 51, 4–6 (2016)CrossRef S.A. Polyzos, A.D. Anastasilakis, Periostin on the road to nonalcoholic fatty liver disease. Endocrine 51, 4–6 (2016)CrossRef
5.
Zurück zum Zitat J.Z. Zhu, H.T. Zhu, Y.N. Dai, C.X. Li, Z.Y. Fang, D.J. Zhao, X.Y. Wan, Y.M. Wang, F. Wang, C.H. Yu, Y.M. Li, Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study. Endocrine 51, 91–100 (2016)CrossRef J.Z. Zhu, H.T. Zhu, Y.N. Dai, C.X. Li, Z.Y. Fang, D.J. Zhao, X.Y. Wan, Y.M. Wang, F. Wang, C.H. Yu, Y.M. Li, Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study. Endocrine 51, 91–100 (2016)CrossRef
6.
Zurück zum Zitat S. Polyzos, J. Kountouras, A. Papatheodorou, E. Katsiki, K. Patsiaoura, E. Zafeiriadou, C. Zavos, E. Papadopoulou, E. Terpos, Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease—Introduction of CHA index. Ann. Hepatol. 12, 749–757 (2013)CrossRef S. Polyzos, J. Kountouras, A. Papatheodorou, E. Katsiki, K. Patsiaoura, E. Zafeiriadou, C. Zavos, E. Papadopoulou, E. Terpos, Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease—Introduction of CHA index. Ann. Hepatol. 12, 749–757 (2013)CrossRef
7.
Zurück zum Zitat D.E. Kleiner, E.M. Brunt, N.M. Van, C. Behling, M.J. Contos, O.W. Cummings, L.D. Ferrell, Y.C. Liu, M.S. Torbenson, A. Unalp-Arida, M. Yeh, A.J. McCullough, A.J. Sanyal, Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005)CrossRef D.E. Kleiner, E.M. Brunt, N.M. Van, C. Behling, M.J. Contos, O.W. Cummings, L.D. Ferrell, Y.C. Liu, M.S. Torbenson, A. Unalp-Arida, M. Yeh, A.J. McCullough, A.J. Sanyal, Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005)CrossRef
8.
Zurück zum Zitat S.A. Polyzos, A.D. Anastasilakis, J. Kountouras, P. Makras, A. Papatheodorou, P. Kokkoris, G.T. Sakellariou, E. Terpos, Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. J. Bone. Miner. Metab. 34, 447–456 (2016)CrossRef S.A. Polyzos, A.D. Anastasilakis, J. Kountouras, P. Makras, A. Papatheodorou, P. Kokkoris, G.T. Sakellariou, E. Terpos, Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. J. Bone. Miner. Metab. 34, 447–456 (2016)CrossRef
9.
Zurück zum Zitat T. Wu, S. Wu, G. Ouyang, Periostin: A new extracellular regulator of obesity-induced hepatosteatosis. Cell Metab. 20, 562–564 (2014)CrossRef T. Wu, S. Wu, G. Ouyang, Periostin: A new extracellular regulator of obesity-induced hepatosteatosis. Cell Metab. 20, 562–564 (2014)CrossRef
10.
Zurück zum Zitat Y. Li, S. Wu, S. Xiong, G. Ouyang, Deficiency of periostin protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis. J. Hepatol. 62, 495–497 (2015)CrossRef Y. Li, S. Wu, S. Xiong, G. Ouyang, Deficiency of periostin protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis. J. Hepatol. 62, 495–497 (2015)CrossRef
11.
Zurück zum Zitat Y. Huang, W. Liu, H. Xiao, A. Maitikabili, Q. Lin, T. Wu, Z. Huang, F. Liu, Q. Luo, G. Ouyang, Matricellular protein periostin contributes to hepatic inflammation and fibrosis. Am. J. Pathol. 185, 786–797 (2015)CrossRef Y. Huang, W. Liu, H. Xiao, A. Maitikabili, Q. Lin, T. Wu, Z. Huang, F. Liu, Q. Luo, G. Ouyang, Matricellular protein periostin contributes to hepatic inflammation and fibrosis. Am. J. Pathol. 185, 786–797 (2015)CrossRef
Metadaten
Titel
Circulating periostin in patients with nonalcoholic fatty liver disease
verfasst von
Stergios A. Polyzos
Jannis Kountouras
Athanasios D. Anastasilakis
Athanasios Papatheodorou
Panagiotis Kokkoris
Evangelos Terpos
Publikationsdatum
13.10.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1144-x

Weitere Artikel der Ausgabe 2/2017

Endocrine 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.